Oncology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Oncology

Oncology

Home News Diseases Conferences Special Reports Multimedia

Brentuximab vedotin + CHP doubles PFS over CHOP in CD30+ peripheral T-cell lymphoma

Roshini Claire Anthony, 11 hours ago

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

Maintenance olaparib provides survival advantage in mutated ovarian cancer

Jairia Dela Cruz, 14 hours ago

The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.

Direct switch to IND/GLY from SFC improves predose FEV1, FVC in COPD patients

14 hours ago

A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.

DPP-4 inhibitors, GLP-1 receptor agonists tied to elevated risk of cholangiocarcinoma

Stephen Padilla, Yesterday

Use of dipeptidyl peptidase-4 (DPP-4), and possibly glucagon-like peptide-1 (GLP-1) receptor agonists, may increase the risk of cholangiocarcinoma in adults with type 2 diabetes (T2D) compared with use of other second- or third-line antidiabetic drugs, but the absolute risk is low, according to a study.

Palbociclib–fulvestrant combo yields overall survival gains in advanced breast cancer

Jairia Dela Cruz, Yesterday

Newly published data from the PALOMA-3 trial confirm the survival advantage of using the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with fulvestrant. The combination prolongs overall survival in patients with hormone-receptor–positive, HER2-negative advanced breast cancer, particularly those who have shown response to previous endocrine therapy, when compared with fulvestrant only.

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh, 4 days ago

Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

MURANO solidifies venetoclax-rituximab combo for relapsed/refractory CLL

Roshini Claire Anthony, 4 days ago

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

Targeted Immunotherapy against PD-L1 in NSCLC

21 Nov 2018

Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.

A report of the first patient in Malaysia who had successfully completed 16 cycles of brentuximab vedotin

19 Sep 2018

In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.^1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.⁴ Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.⁵

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018

At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Treatment-free remission: Who, how and why?

21 May 2018

At the recent American Society of Haematology Annual Meeting 2017, Professor François-Xavier Mahon reviewed recent studies related to tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukaemia (CML) who have achieved sustained deep molecular response (DMR).

Improving survival with CDK4/6 inhibitors in postmenopausal HR+/HER2-metastatic breast cancer patients

Rachel Soon, 28 Feb 2018

Recent developments on CDK 4/6 trials in patients with oestrogen receptor-positive metastatic breast cancers (ER+ MBC) were reviewed at ESMO and ASCO 2017.

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh, 07 Dec 2018

MURANO solidifies venetoclax-rituximab combo for relapsed/refractory CLL

Roshini Claire Anthony, 07 Dec 2018

Apalutamide equally beneficial in Asians with nmCRPC

Elvira Manzano, 05 Dec 2018

Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.

Elaine Soliven, 05 Dec 2018

Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.

Beta blockers, renin-angiotensin inhibitors may thwart anthracycline-induced cardiotoxicity

Jairia Dela Cruz, 05 Dec 2018

Beta blockers and/or renin-angiotensin inhibitors appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.

Breast self-examination awareness programs improve knowledge, attitudes, practice

Tristan Manalac, 05 Dec 2018

Despite good attitudes toward breast self-examination, being well-informed about the procedure may still not translate to improvements in practice among female healthcare workers, reports a Philippine study presented at the recently concluded European Society for Medical Oncology (ESMO) Asia 2018 Congress.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!